General Updates

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com June 30, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/ Madam, Sub: Integrated Annual Report for the FY 2025-26 In compliance with the provisions of the Companies Act, 2013 (“Act”), the rules made thereunder, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended from time to time, please find enclosed the Integrated Annual Report, Business Responsibility and Sustainability Report (“BRSR”) and the Notice of the 42nd Annual General Meeting (“AGM”) for the financial year 2025-26. Pursuant to the provisions of Regulation 34(1) of the SEBI Listing Regulations, the Integrated Annual Report of the Company for the FY 2025-26 is being sent through electronic mode to the Members, who have registered their e-mail addresses with the Company/Registrar and Transfer Agent/ Depositories. In addition, pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, a letter is also being sent to the Members whose email addresses are not registered, providing the web-link where the Annual Report is uploaded on website. The Integrated Annual Report FY 2025-26 is also available on the Company’s website and can be accessed at the following link: Integrated Annual Report FY 2025-26 This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer and Head-CSR Corporate overview Financial statements 02 Who we are 267 Standalone financial 04 Message from Chairman and statements (Ind AS) Co-Chairman & MD 370 Consolidated financial 06 Our global presence statements (Ind AS) 08 Key performance indicators 495 Extract of IFRS consolidated CORPORATE financial statements 10 Board of directors OVERVIEW 12 Management council Strategic review Annexures 14 Approach to reporting 498 Independent assurance statement 16 Our strategy pillars 507 GRI content index 22 Our value creation model 518 Disclosures in accordance with Art. 24 Building the future responsibly 964b Swiss Code of Obligations 26 Access, Affordability, 519 Glossary and Innovation 522 ISSB disclosures on IFRS S1 & S2 38 Helping our people realise 539 Notice of 42nd Annual General Meeting Contents their full potential 48 Empowering the communities around us 54 Building a greener tomorrow 66 Leading responsibly 91 80 Stakeholder engagement and materiality assessment STATUTORY 86 Risk management 88 Awards and recognitions REPORTS Statutory Reports 91 Corporate information 92 Management discussion and analysis 120 Five years at a glance and key financial ratios 122 Board’s report and annexures 14 156 Business responsibility and Click on any section title sustainability report to go directly to that part STRATEGIC 215 Corporate governance report of the document. REVIEW 251 Additional shareholders’ information 02-13 Integrated Annual Report 2025-26 Corporate Overview Strategic Review Statutory Reports Financial Statements Our Purpose Our Principles Our Leadership Behaviours We accelerate access to affordable and innovative medicines because Empathy Quality Aspire for market leadership Who Good Health Can't Wait. We deeply comprehend the needs of We are committed to embedding Lead the way as a pioneer, taking our patients and partners, setting us quality into every aspect of our every step needed to be first to apart from others products and processes to exceed market with cost-leadership and we are strive for a commanding market share stakeholder expectations. Dynamism in key markets. We tackle challenges that few Collaboration and teamwork others can, doing so with speed Choose speed and depth everyday Our Promises We harness expertise and and adaptability Act on decisions swiftly by resources from across our global Dr. Reddy's Laboratories Limited (Dr. Reddy's) is a weighing the risks and rewards. Bringing network to deliver greater value for Progress with urgency while maintaining global pharmaceutical company headquartered in Expensive medicines within reach our stakeholders. a thorough understanding. Hyderabad, India. Steered by our purpose of Good Health Can't Wait, we strive to broaden access to Addressing Respect for the individual Unleash the potential in people Unmet patient needs We are devoted to fostering a work Inspire the best in those around affordable and innovative medicines. Our portfolio Our Values environment that embraces diverse you. Support them in achieving their includes APIs, generic formulations including Helping Guided by our commitment to perspectives and honours the full potential. biosimilars, OTC products, innovative products, Patients manage disease better delivering affordable and innovative dignity of both work and individuals. medicines for healthier lives, we Innovate to create value and custom pharmaceutical services, with a strong Enabling foster a culture of innovation and Sustainability Seek out new solutions that make learning, while consistently striving focus on key therapeutic areas like Oncology, Our partners to ensure our medicines are We deliver value for our a meaningful difference in the for higher standards of excellence. Central Nervous System, Pain Management, available where needed stakeholders in a way that lives of patients and address the needs of customers. safeguards our natural environment Gastro-Intestinal, Cardiovascular. We serve Working Integrity and transparency and supports the well-being several major markets including the USA, India, With partners to help them succeed We maintain the highest standards of the communities where Be accountable for end results of honesty and openness in Take ownership from start to finish, Russia & CIS, China, Brazil, and Europe. we live and work. all our dealings. and be responsible for the outcomes delivered to patients, customers, and Safety Productivity the organisation. We are dedicated to ensuring safe We aim to accomplish more with fewer resources by embracing working environments through Excellence in execution the ongoing enhancement of our innovation, continuous improvement, Champion continuous improvement infrastructure, work practices, and a strong emphasis on and strive for excellence in execution to and behaviours. achieve superior outcomes. reducing waste. 02 03 02-13 Integrated Annual Report 2025-26 Corporate Overview Strategic Review Statutory Reports Financial Statements We will continue to strengthen our base business while building future growth drivers across peptides, biosimilars, consumer healthcare, and innovation-led therapies. Message from G V Prasad Chairman and Co-Chairman and Managing Director Co-Chairman & MD Dear Shareholders, business is at an inflection point, and several promising candidates in Sustainability we are taking focused steps to scale it the pre-clinical stage. We remain The year was marked by a We continued to make steady into a meaningful growth driver. committed to building a differentiated challenging external environment, progress on our sustainability global oncology business through a with geopolitical uncertainties, rising agenda. Our transition towards Strategic Priorities and combination of internal innovation protectionism, and evolving global renewable energy sources across Execution and partnerships. trade dynamics. Despite this, our operations has strengthened, and businesses demonstrated resilience, Our strategy remains anchored on we maintained water positivity supported by disciplined execution three priorities: In APIs and services, competitive across our sites. Our EcoVadis score pressures persist as customers and a continued focus on • Str [Showing first 8,000 characters — download PDF for full document]